drugset / Trial / NCT00972179
Safety Study of Tezepelumab (AMG 157) in Healthy Adults
RandomizedSequentialDouble-blindTreatment
Summary
The primary objective is to evaluate the safety, tolerability, and immunogenicity of multiple-dose administration of tezepelumab in healthy adults.
Timeline
- Start
- 2009-09-15
- Primary completion
- 2011-01-09
- Completion
- 2011-01-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tezepelumab | Monoclonal antibody | 35 mg | Subcutaneous |
| Subject | Tezepelumab | Monoclonal antibody | 210 mg | Subcutaneous |
| Subject | Tezepelumab | Monoclonal antibody | 700 mg | Subcutaneous |
Indications
No indication recorded.